Sanofi and Orano Unite to Pioneer Next-Generation Radioligand Therapies

Sanofi and Orano Med, a subsidiary of the Orano Group specializing in targeted alphatherapies for oncology, have entered into a strategic partnership to advance the fight against rare cancers by accelerating the development of next-generation radioligand therapies (RLTs). This collaboration brings together Sanofi’s global pharmaceutical expertise with Orano Med’s established radioligand pipeline.

Under this agreement, both companies will invest in a new entity that will operate under the Orano Med brand, focusing on the discovery and clinical advancement of cutting-edge RLTs. These therapies will be based on lead-212 (212Pb) alpha-emitting isotopes, known for their precision in targeting and killing cancer cells. This partnership builds on Sanofi's recent exclusive licensing deal with Orano Med and RadioMedix to further develop AlphaMedix™, a late-stage RLT project targeting rare cancers.

The concept behind targeted alpha therapy is simple yet groundbreaking: biological vectors are used to deliver potent alpha-emitting radioisotopes directly to cancer cells, ensuring precision in treatment while minimizing damage to healthy tissue. This innovative approach has the potential to redefine treatment standards for rare cancers, offering hope for extended survival and improved quality of life for patients.

Paul Hudson, CEO at Sanofi, stated, “We are excited to partner with Orano in establishing a French pioneer that unites our respective expertise in biopharma and nuclear technology to drive groundbreaking progress in the fight against cancer. As a French biopharmaceutical company, we are deeply committed to fostering and enabling innovation in our home country. This collaboration is part of a broader effort to strengthen our ties within the scientific community, both in France and globally, with the goal of advancing the development of cutting-edge treatments for patients.”

Nicolas Maes, CEO at Orano Group, said, “The success of Orano Med is an example of our group's ability to diversify beyond our core nuclear business. By applying our expertise in nuclear materials to fields like targeted alpha therapies, we are demonstrating that nuclear technology can have a positive societal impact, not just for energy and climate, but also for human health. This innovation reflects Orano's commitment to exploring new opportunities and taking bold steps to address some of the world’s most pressing challenges.”

Sanofi’s investment will bolster Orano Med's efforts, empowering the company to expedite the advancement of its innovative pipeline of lead-212 based therapies. With this support, Orano Med can tap into its specialized expertise in discovering and developing cutting-edge radioligand treatments.

Additionally, Orano Med has established a distinctive global industrial platform, supported by a substantial stockpile of raw materials and a patented manufacturing process. This platform is designed to guarantee a steady, independent, and scalable supply of lead-212 based therapies, ensuring patients worldwide have reliable access to these next-generation treatments.